Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of ASTX727 in MDS and AML
NCT03813186Phase 1Completed
- Sponsor
- Astex Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of inqovi in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Area under the concentration-time curve from time 0 to t hours at 6 months, Area under the concentration-time curve from time 0 to 8 hours and 3 more. Started Nov 2018; status: completed.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03813186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813186.